Currently, immunotherapies are only administered intravenously in healthcare settings. The study will assess whether a new formulation of atezolizumab can be safely and effectively administered subcutaneously by nurses at patients’ homes.
The clinical trial is the first to assess whether a subcutaneous immunotherapy can be administered at home.
“Many types of drugs are now being delivered subcutaneously at home for several conditions, and we hypothesize that this method of drug delivery can also be successful for cancer patients,” lead investigator Jorge Nieva, MD, a medical oncologist and lung cancer specialist with Keck Medicine, said in a March 28 news release.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
